Overview

Denosumab for the Treatment of Adult LCH

Status:
Active, not recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
This study is aiming to evaluate the efficacy of denosumab among adult patients suffering from Langerhans Cell Histiocytosis (LCH).
Phase:
Phase 2
Details
Lead Sponsor:
Hellenic Society for the Study of Bone Metabolism
Treatments:
Denosumab